Skip to Content

News and Publications

News Releases and Articles

Novel Gene Therapy for Bladder Cancer Shows Strong Results in Animal Studies - Gene therapy that causes the bladder to act like a “bioreactor” to produce and secrete the anti-cancer agent interferon-alpha has shown dramatic benefits in preclinical tests, say researchers at The University of Texas MD Anderson Cancer Center. (MD Anderson News Release, 09/07/04)

SPORE Grants Fuel Genitourinary Cancer Program [need link]- Two prestigious grants for bladder and prostate cancers let MD Anderson researchers build upon important advances they've already made. (Conquest, Fall 2001)

MD Anderson Receives SPORE Grant for Bladder Cancer Research - Institution is first to hold two special federal grants for genitourinary cancers. (MD Anderson News Release, 10/22/01)

Publications

2013

Siefker-Radtke, AO, Dinney, CP, Shen, Y, Williams, DL, Kamat, A, Grossman, HB, Millikan, RE. A phase II clinical trial of sequential neoadjuvant chemotherapy with Ifosfamide, Doxorubicin, and Gemcitabine, followed by Cisplatin, Gemcitabine, and Ifosfamide in locally advanced urothelial cancer: final results. Cancer. 119(3): 540-547, 2013.

Dayyani F, Czerniak BA, Sircar K, Munsell MF, Millikan RE, Dinney CP, Siefker-Radtke AO. Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. J Urol. 189(5): 1656-1661, 2013.

Ke HL, Chen M, Ye Y, Hildebrandt MA, Wu WJ, Wei H, Huang M, Chang DW, Dinney CP, Wu X. Genetic variations in micro-RNA biogenesis genes and clinical outcomes in non-muscle-invasive bladder cancer. Carcinogenesis. 34(5): 1006-1011, 2013.

Tran MN, Choi W, Wszolek MF, Navai N, Lee IL, Nitti G, Wen S, Flores ER, Siefker-Radtke A, Czerniak B, Dinney C, Barton M, McConkey DJ. The p63 protein isoform ΔNp63α inhibits epithelialmesenchymal transition in human bladder cancer cells: role of MIR-205. J Biol Chem. 288(5): 3275-3288, 2013.

Cheng T, Roth B, Choi W, Black PC, Dinney C, McConkey DJ. Fibroblast growth factor receptors-1 and -3 play distinct roles in the regulation of bladder cancer growth and metastasis: implications for therapeutic targeting. PLoS One.  8(2): e57284, 2013.

Jäger W, Horiguchi Y, Shah J, Hayashi T, Awrey S, Gust KM, Hadaschik BA, Matsui Y, Anderson S, Bell RH, Ettinger S, So AI, Gleave ME, Lee IL, Dinney CP, Tachibana M, McConkey DJ, Black PC. Hiding in plain view: genetic profiling reveals decades old cross contamination of bladder cancer cell line KU7 with HeLa. J Urol.190(4): 1404-1409, 2013.

Gust KM, McConkey DJ, Awrey S, Hegarty PK, Qing J, Bondaruk J, Ashkenazi A, Czerniak B, Dinney CP, Black PC. Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer. Mol Cancer Ther. 12(7):1245-1254, 2013.

Lynch SP, Shen Y, Kamat A, Grossman HB, Shah JB, Millikan RE, Dinney CP, Siefker-Radtke A. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and longterm outcomes: results from a retrospective study at the MD Anderson Cancer Center. Eur Urol. 64(2):307-313, 2013.

Sacerdote C, Guarrera S, Ricceri F, Pardini B, Polidoro S, Allione A, Critelli R, Russo A, Andrew AS, Ye Y, Wu X, Kiemeney LA, Bosio A, Casetta G, Cucchiarale G, Destefanis P, Gontero P, Rolle L, Zitella A, Fontana D, Vineis P, Matullo G. Polymorphisms in the XRCC1 gene modify survival of bladder cancer patients treated with chemotherapy. Int J Cancer. 15;133(8):2004-2009, 2013.

2012

Akli S, Zhang XQ, Bondaruk J, Tucker SL, Czerniak PB, Benedict WF, Keyomarsi K. Low molecular weight cyclin E is associated with p27- resistant, high-grade, high-stage and invasive bladder cancer. Cell Cycle. 11(7): 1468-1476, 2012.

Majewski T, Spiess PE, Bondaruk J, Black P, Clarke C, Benedict W, Dinney CP, Grossman HB, Tang KS, Czerniak B. Detection of bladder cancer using proteomic profiling of urine sediments. PLoS One. 7(8): e42452, 2012.

Lee S, Lee I, Jung Y, McConkey D, Czerniak B. In-frame cDNA library combined with protein complementation assay identifies ARL11-binding partners. PLoS One. 7(12): e52290, 2012.

Andrew AS, Hu T, Gu J, Gui J, Ye Y, Marsit CJ, Kelsey KT, Schned AR, Tanyos SA, Pendleton EM, Mason RA, Morlock EV, Zens MS, Li Z, Moore JH, Wu X, Karagas MR. HSD3B and gene-gene interactions in a pathway-based analysis of genetic susceptibility to bladder cancer. PLoS One. 7(12): e51301, 2012.

Wei H, Kamat AM, Aldousari S, Ye Y, Huang M, Dinney CP, Wu X. Genetic variations in the transforming growth factor beta pathway as predictors of bladder cancer risk. PLoS One. 2012;7(12): e51758, 2012.

Marquis L, Tran M, Choi W, Lee IL, Huszar D, Siefker-Radtke A, Dinney C, McConkey DJ. p63 expression correlates with sensitivity to the Eg5 inhibitor ZD4877 in bladder cancer cells. Cancer Biol Ther. 13(7): 477-486, 2012.

Choi W, Shah JB, Tran M, Svatek R, Marquis L, Lee IL, Yu D, Adam L, Wen S, Shen Y, Dinney C, McConkey DJ, Siefker-Radtke A. p63 expression defines a lethal subset of muscle-invasive bladder cancers. PLoS One.  7(1):e30206, 2012.

Dickstein RJ, Nitti G, Dinney CP, Davies BR, Kamat AM, McConkey DJ. Autophagy limits the cytotoxic effects of the AKT inhibitor AZ7328 in human bladder cancer cells. Cancer Biol Ther. 13(13): 1325-1338, 2012.

Smith SC, Baras AS, Owens CR, Dancik G, Theodorescu D. Transcriptional signatures of Ral GTPase are associated with aggressive clinicopathologic characteristics in human cancer. Cancer Res. 72(14): 3480-3491, 2012.

Fu YP, Kohaar I, Rothman N, Earl J, Figueroa JD, Ye Y, Malats N, Tang W, Liu L, Garcia-Closas M, Muchmore B, Chatterjee N, Tarway M, Kogevinas M, Porter-Gill P, Baris D, Mumy A, Albanes D, Purdue MP, Hutchinson A, Carrato A, Tardón A, Serra C, García-Closas R, Lloreta J, Johnson A, Schwenn M, Karagas MR, Schned A, Diver WR, Gapstur SM, Thun MJ, Virtamo J, Chanock SJ, Fraumeni JF Jr, Silverman DT, Wu X, Real FX, Prokunina-Olsson L. Common genetic variants in the PSCA gene influence gene expression and bladder cancer risk. Proc Natl Acad Sci U S A. 109(13):4974-4979, 2012.

Chang J, Dinney CP, Huang M, Wu X, Gu J. Genetic variants in telomere-maintenance genes and bladder cancer risk. PLoS One. 7(2): e30665, 2012.

Andrew AS, Hu T, Gu J, Gui J, Ye Y, Marsit CJ, Kelsey KT, Schned AR, Tanyos SA, Pendleton EM, Mason RA, Morlock EV, Zens MS, Li Z, Moore JH, Wu X, Karagas MR. HSD3B and gene-gene interactions in a pathway-based analysis of genetic susceptibility to bladder cancer. PLoS One. 2012;7(12):e51301, 2012.

2011

Yang Z1, Zhang XQ, Dinney CN, Benedict WF. Direct cytotoxicity produced by adenoviral-mediated interferon in interferon resistant bladder cancer cells involves ER stress and caspase 4 activation. Cancer Gene Ther. 18(9): 609-16, 2011.

2010

Inamoto T, Czerniak BA, Dinney CP, Kamat, AM. Cytoplasmic mislocalization of the orphan nuclear receptor nurr1 is a prognostic factor in bladder cancer. Cancer. 15; 116(2):340-346, 2010.

Clague J, Cinciripini P, Blalock J, Wu X, Hudmon KS. The D2 dopamine receptor gene and nicotine dependence among bladder cancer patients and controls. Behav Genet.  40(1):49-58, 2010.

Zhang XQ, Dunner K, Benedict WF. Autophagy is induced by adenoviral-mediated interferon treatment in interferon resistant bladder cancer and normal urothelial cells as a cell death protective mechanism but not by the bystander factors produced. Cancer Gene Ther. 17(8): 579-584, 2010.

2009

Kim J, Jonasch E, Alexander A, Short JD, Cai S, Wen S, Tsavachidou D, Tamboli P, Czerniak BA, Do KA, Wu KJ, Marlow LA, Wood CG, Copland JA, Walker CL. Cytoplasmic sequestaration of p27 via AKT phosphorylation in renal cell carcinoma. Clin Cancer Res. 15(1): 81-90, 2009.

Kassouf W, Agarwal PK, Grossman HB, Leibovici D, Munsell MF, Siefker-Radtke A, Pisters LL, Swanson DA, Dinney CP, Kamat AM. Outcome of patients with pN+ disease after preoperative chemotherapy and radical cystectomy. Urology. 73(1): 147-52, 2009.

Guo CC, Tamboli P, Czerniak B. Micropapillary variant of urothelial carcinoma in the upper urinary tract: a clinicopathologic study of 11 cases. Arch Pathol Lab Med 133(1):62-66, 2009.

Guo CC, Zuo G, Cao D, Troncoso P, Czerniak B. Prostate cancer of transition zone origin lacks TMPRSS2-ERG gene fusion. Mod Pathol. 22(7):866-871, 2009.

Guo CC, Gomez E, Tamboli P, Bondaruk J, Kamat A, Bassett R, Dinney CP, Czerniak B. Squamous cell carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical study of 16 cases. Hum Pathol. 40(10):1448-1452, 2009.

Guo CC, Punar M, Contreras AL, Tu SM, Pisters L, Tamboli P, Czerniak B. Testicular germ cell tumors with sarcomatous components: an analysis of 33 cases. Am J Surg Pathol 33(8):1173-1178, 2009.

Cassidy A, Wang W, Wu X, Lin J. Risk of urinary bladder cancer: a case-control analysis of industry and occupation. BMC Cancer. 9(1): 443, 2009.

Wu X, Ye Y, Kiemeney LA, Sulem P, Rafnar T, Matullo G, Seminara D, Yoshida T, Saeki N, Andrew AS, Dinney CP, Czerniak B, Zhang ZF, Kiltie AE, Bishop DT, Vineis P, Porru S, Buntinx F, Kellen E, Zeegers MP, Kumar R, Rudnai P, Gurzau E, Koppova K, Mayordomo JI, Sanchez M, Saez B, Lindblom A, de Verdier P, Steineck G, Mills GB, Schned A, Guarrera S, Polidoro S, Chang SC, Lin J, Chang DW, Hale KS, Majewski T, Grossman HB, Thorlacius S, Thorsteinsdottir U, Aben KK, Witjes JA, Stefansson K, Amos CI, Karagas MR, Gu J.  Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet. 41(9): 991-995, 2009.

Lin J, Kamat A, Gu J, Chen M, Dinney CP, Forman MR, Wu X. Dietary intake of vegetables and fruits and the modification effects of GSTM1 and NAT2 genotypes on bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 18(7): 2090-2097, 2009.

Cassidy A, Wang W, Wu X, Lin J. Risk of urinary bladder cancer: a case-control analysis of industry and occupation. BMC Cancer. 9(1): 443, 2009.

Chen M, Cassidy A, Gu J, Delclos GL, Zhen F, Yang H, Hildebrandt MA, Lin J, Ye Y, Chamberlain RM, Dinney CP, Wu X. Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk. Carcinogenesis. (12): 2047-2052, 2009.

McConkey DJ, Choi W, Marquis L, Martin F, Williams MB, Shah J, Svatek R, Das A, Adam L, Kamat A, Siefker-Radtke A, Dinney C. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev. 28(3-4):335-344, 2009.

McConkey DJ, Dinney CP. The molecular, the bad, and the ugly: preventing bladder cancer via mTOR inhibition. Cancer Prev Res. 2: 1001-1002, 2009.

Siefker-Radtke AO, Kamat AM, Grossman HB, Williams DL, Qiao W, Thall PF, Dinney CP, Millikan RE. Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin, and etoposide/cisplatin in small-cell urothelial cancer. J Clin Oncol. 27(16): 2592-2597, 2009.

Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, Calin G, Wang H, Siefker-Radtke A, McConkey D, Bar-Eli M, Dinney C. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res. 15: 5060-5072, 2009.

Fisher MB, Zhang XQ, McConkey DJ, Benedict WF. Measuring soluble forms of extracellular cytokeratin 18 identifies both apoptotic and necrotic mechanisms of cell death produced by adenoviral-mediated interferon alpha: possible use as a surrogate marker. Cancer Gene Ther.  16: 567-72, 2009.

Zhou J, Zhang XQ, Ashoori F, McConkey DJ, Knowles MA, Dong L, Benedict WF. Early RB94-produced cytotoxicity in cancer cells is independent of caspase activation or 50 kb DNA fragmentation. Cancer Gene Ther. 16: 13-9, 2009.

2008

Inamoto T, Papineni S, Chintharlapalli S, Cho SD, Safe S, Kamat AM. 1,1-Bis(3'-indolyl)-1-(p-chlorophenyl)methane activates the orphan nuclear receptor Nurr1 and inhibits bladder cancer growth. Mol Cancer Ther. 7(12):3825-33, 2008.

Yang H, Dinney CP, Ye Y, Zhu Y, Grossman HB, and Wu X. Evaluation of genetic variants in MicroRNA-related genes and risk of bladdercancer. Cancer Res. 68(7): 2530-2537, 2008.

Pirollo KF, Rait A, Zhou Q, Zhang X-Q, Zhou J, Chang-Soo K, Benedict WF and Chang EH. Tumor-targeting nanocomplex delivery of novel tumor suppressor RB94 chemosensitizes bladder carcinoma cells in vitro and in vivo. Clin Cancer Res. (14)7: 2190 - 2198, 2008.

Harris LD, La Cerda JD, Tuziak T, Rosen D, Xiao L, Shen Y, Sabichi AL, Czerniak B, Grossman HB. Analysis of the expression of biomarkers in urinary bladder cancer using a tissue microarray. Mol Carcinog. 47(9):678-685, 2008.

Shivapurkar N, Stastny V, Xie Y, Prinsen C, Frenkel E, Czerniak B, Thunnissen FB, Minna JD, Gazdar AF. Differential methylation of a short CpG-rich sequence within exon 1 of TCF21 gene: a promising cancer biomarker assay. Cancer Epidemiol Biomarkers Prev. 17(4):995-1000, 2008.  

Majewski T, Lee S, Jeong J, Yoon DS, Kram A, Kim MS, Tuziak T, Bondaruk J, Lee S, Park WS, Tang KS, Chung W, Shen L, Ahmed SS, Johnston DA, Grossman HB, Dinney CP, Zhou JH, Harris RA, Snyder C, Filipek S, Narod SA, Watson P, Lynch HT, Gazdar A, Bar-Eli M, Wu XF, McConkey DJ, Baggerly K, Issa JP, Benedict WF, Scherer SE, Czerniak B.  Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy. Lab Invest. 88(7):694-721, 2008.  

Brait M, Begum S, Carvalho AL, Dasgupta S, Vettore AL, Czerniak B, Caballero OS, Westra WH, Sidransky D, Hoque MO. Aberrant promoter methylatio of multiple genes during pathogenesis of bladder cancer. Cancer Epidemiol Biomarkers Prev. 17(10):2786-94, 2008.

Shivapurkar N, Stastny V, Xie Y, Prinsen C, Frenkel E, Czerniak B, Thunnissen FB, Minna JD, Gazdar AF. Differential methylation of a short CpG-rich sequence within exon 1 of TCF21 gene: a promising cancer biomarker assay. Cancer Epidemiol Biomarkers Prev. 17(4):995-1000, 2008.

Shivapurkar N, Stastny V, Okumura N, Girard L, Xie Y, Prinsen C, Thunnissen FB, Wistuba II, Czerniak B, Frenkel E, Roth JA, Liloglou T, Xinarianos G, Field JK, Minna JD, Gazdar AF. Cytoglobin, the newest member of the globin family, functions as atumor suppressor gene. Cancer Res. 68:7448-7456, 2008.  

Park HS, Park WS, Bondaruk J, Tanaka N, Katayama H, Lee S, Spiess PE, Steinberg JR, Wang Z, Katz RL, Dinney C, Elias KJ, Lotan Y, Naeem RC, Baggerly K, Sen S, Grossman HB, Czerniak B.  Quantitation of aurora kinase A gene copy  number in urine sediments and bladder cancer detection.  JNCI. 100:1401-1411, 2008.

Gu J, Horikawa Y, Chen M, Dinney CP, Wu X. Benzo(a)pyrene diol epoxide-induced chromosome 9p21 aberrations are associated with increased risk of bladder cancer. Cancer Epidemiol Biomarkers Prev. 17(9):2445-50, 2008.

Wu X, Ros MM, Gu J, Kiemeney L. Epidemiology and genetic susceptibility to bladder cancer. BJU Int. 102(9 Pt B): 1207-1215, 2008.

Zhang X, Dong L, Chapman E, Benedict WF. Conditioned medium from Ad-IFN-alpha-infected bladder cancer and normal urothelial cells is cytotoxic to cancer cells but not normal cells: further evidence for a strong bystander effect. Cancer Gene Ther. 12: 817-822, 2008.

Black PC, Brown GA, Inamoto T, Shrader M, Arora A, Siefker-Radtke AO, Adam L, Theodorescu D, Wu X, Munsell MF, Bar-Eli M, McConkey DJ, Dinney CP. Sensitivity to epidermal growth factor receptorinhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res. 14: 1478-1486, 2008.

Kassouf W, Brown GA, Black PC, Fisher MB, Inamoto T, Luongo T, Gallagher D, Bar-Eli M, McConkey DJ, Adam L, Dinney CP. Is vascular endothelial growth factor modulation a predictor of the therapeutic efficacy of gefitinib for bladder cancer? J Urol. 180: 1146-1153, 2008.

Kassouf W, Black PC, Tuziak T, Bondaruk J, Lee S, Brown GA, Adam L, Wei C, Baggerly K, Bar-Eli M, McConkey D, Czerniak B, Dinney CP. Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer.  J Urol 179: 353-358, 2008.

2007

Lee S, Jeong J, Majewski T, Scherer S, Kim MS, Tuziak T, Tang KS, Baggerly K, Grossman HB, Zhou JH, Shen L, Bondaruk J, Ahmed SS, Samanta S, Spiess PE, Wu X, Filipek S, McConkey D, Bar-Eli M, Issa JP, Benedict WF, and Czerniak B. Forerunner genes contiguous to RB1 contribute to the development of in situ neoplasia. PNAS. 104(34): 13732-13737, 2007.

Zhang X, Yang Z, Dong L, Papageorgiou A, McConkey DJ, and Benedict WF. Adenoviral-mediated interferon alpha overcomes resistance to the interferon protein in various cancer types and has marked bystander effects. Cancer Gene Ther. 14(3): 241-250, 2007.

Adam L, Black PC, Kassouf W, Eve B, McConkey D, Munsell MF, Benedict WF, and Dinney CP. Adenoviral mediated interferon-alpha 2b gene therapy suppresses the pro-angiogenic effect of vascular endothelial growth factor in superficial bladder cancer. J Urol. 177(5): 1900-1906, 2007.

Nagabhushan TL, Maneval DC, Benedict WF, Wen SF, Ihnat PM, Engler H, and Connor RJ. Enhancement of intravesical delivery with Syn3 potentiates interferon-Ą2b gene therapy for superficial bladder cancer. Cytokine Growth Factor Review. 18: 389-394, 2007.

Black PC, Brown GA, and Dinney CP. Clinical and therapeutic significance of aberrant differentiation patterns in bladder cancer. Expert Review of Anticancer Therapy. 7(7):1015-1026, 2007.

Adam L, Black PC, Kassouf W, Eve B, McConkey D, Munsell MF, Benedict WF, and Dinney CP. Adenoviral mediated interferon-alpha 2b gene therapy suppresses the pro-angiogenic effect of vascular endothelial growth factor in superficial bladder cancer. J Urol. 177(5): 1900-1906, 2007.

Zhu Y, Lai M, Yang H, Lin J, Huang M, Grossman HB, Dinney CP, and Wu X. Genotypes, haplotypes and diplotypes of XPC and risk of bladder cancer. Carcinogenesis. 28: 698-703, 2007.

Wu X, Lin X, Dinney CP, Gu J, and Grossman HB. Genetic polymorphism in bladder cancer. Frontiers in Bioscience. 12: 192-213, 2007.

Shrader M, Pino MS, Lashinger L, Bar-Eli M, Adam L, Dinney CP, and McConkey DJ. Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression. Cancer Res. 67: 1430-1435, 2007.

Shrader M, Pino MS, Brown G, Black P, Adam L, Bar-Eli M, Dinney CP, and McConkey DJ. Molecular correlates of gefitinib responsiveness in human bladder cancer cells. Molecular Cancer Therapeutics. 6: 277-285, 2007.

Kassouf W, Spiess PE, Brown GA, Munsell MF, Grossman HB, Siefker-Radtke A, Dinney CP, and Kamat AM. P0 Stage at Radical Cystectomy for Bladder Cancer Is Associated with Improved Outcome Independent of Traditional Clinical Risk Factors. European Urology. 2007.

Kader AK, Liu J, Shao L, Dinney CP, Lin J, Wang Y, Gu J, Grossman HB, and Wu X. Matrix metalloproteinase polymorphisms are associated with bladder cancer invasiveness.Clin Cancer Res. 13: 2614-2620, 2007.

Zhao H, Lin J, Grossman HB, Hernandez LM, Dinney CP and Wu X. Dietary isothiocyanates, GSTM1, GSTT1, NAT2 polymorphisms and bladder cancer risk. International Journal of Cancer. 120: 2208-2213, 2007.

Huang M, Dinney CP, Lin X, Lin J, Grossman HB and Wu X. High-order interactions among genetic variants in DNA base excision repair pathway genes and smoking in bladder cancer susceptibility. Cancer Epidemiol Biomarkers Prev. 16(1):84-91, 2007.

Spiess PE, Kassouf W, Steinberg JR, Tuziak T, Hernandez M, Tibbs RF, Czerniak B, Kamat AM, Dinney CP, and Grossman HB. Review of the MD Anderson experience in the treatment of bladder sarcoma. Urologic Oncology. 25(1):38-45, 2007.

Agarwal PK, Black PC, McConkey DJ, Dinney CP. Emerging drugs for targeted therapy of bladder cancer. Expert Opin Emerg Drugs. 12: 435-448, 2007.

Villares GJ1, Zigler M, Blehm K, Bogdan C, McConkey D, Colin D, Bar-Eli M. Targeting EGFR in bladder cancer. World J Urol. 25: 573-579. 2007.

Papageorgiou A, Dinney CP, McConkey DJ. Interferon-alpha induces TRAIL expression and cell death via an IRF-1-dependent mechanism in human bladder cancer cells. Cancer Biol Ther.  6: 872-879, 2007.

Katayama H, Sasai K, Czerniak BA, Carter JL, Sen S.  Aurora-A kinase phosphorylation of Aurora-A kinase interacting protein (AIP) and stabilization of the enzyme-substrate complex.  J Cell Biochem. 102(5): 1318-1331, 2007.  

Kassouf W, Black PC, Tuziak T, Bondaruk J, Lee S, Brown GA, Adam L, Wei C, Baggerly K, Bar-Eli M, McConkey D, Czerniak B, Dinney CP.  Distinctive Expression Pattern of ErbB Family Receptors Signifies an Aggressive Variant of Bladder Cancer.  J Urol. 179:353-358, 2007.

2006

Sabichi A, Keyhani A, Tanaka N, Delacerda J, Lee IL, Zou C, Zhou JH, Benedict WF, and Grossman HB. Characterization of a panel of cell lines derived from urothelial neoplasms: genetic alterations, growth in vivo and the relationship of adenoviral mediated gene transfer to coxsackie adenovirus receptor expression. J Urol. 175(3 Pt 1): 1133-1137, 2006.

Kim MS, Jeong J, Majewski T, Kram A, Yoon DS, Zhang RD, Li JZ, Ptaszynski K, Kuang TC, Zhou JH, Sathyanarayana UG, Tuziak T, Johnston DA, Grossman HB, Gazdar AF, Scherer SE, Benedict WF, and Czerniak B. Evidence for alternative candidate genes near RB1 involved in clonal expansionof in situ urothelial neoplasia. Lab Invest. 86(2): 175-190, 2006.

Tao Z, Connor RJ, Ashoori F, Dinney CP, Munsell M, Philopena JA, and Benedict WF. Efficacy of a single intravesical treatment with Ad-IFN/Syn 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation. Cancer Gene Ther. 13(2): 125-130. 2006.

Papageorgiou A, Kamat A, Benedict WF, Dinney C, and McConkey DJ.  Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells. Mol Cancer Ther. 5: 3032-3041, 2006.

Siefker-Radtke AO. Urachal carcinoma:surgical and chemotherapeutic options. Expert Rev Anticancer Ther. 6/12: 1715-1721, 2006.

Black PC BG, and Dinney CP. Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer. Journal of Clinical Oncology. 24: 5528-5535, 2006.

Brown GA, Busby JE, Wood CG, Pisters LL, Dinney CP, Swanson DA, Grossman HB, Pettaway CA, Munsell MF, Kamat AM, and Matin SF. Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm? BJU Int. 98(6): 1176-1180, 2006.

Kader AK, Shao L, Dinney CP, Schabath MB, Wang Y, Liu J, Gu J, Grossman HB, and Wu X. Matrix metalloproteinase polymorphisms and bladder cancer risk. Cancer Res. 66(24): 11644-11648, 2006.

Papageorgiou A, Kamat A, Benedict WF, Dinney C, and McConkey DJ. Combination therapy with IFN-{alpha} plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells.  Molecular Cancer Ther. 5(12): 3032-3041, Dec 2006.

Spiess PE, Kassouf W, Brown G, Highshaw R, Wang X, Do KA, Kamat AM, Czerniak B, Dinney CP, and Grossman HB. Immediate versus staged urethrectomy in patients at high risk of urethral recurrence: is there a benefit to either approach? Urology. 67(3): 466-471, 2006.

Zhu Y, Lai M, Yang H, Lin J, Huang M, Grossman HB, Dinney CP, and Wu X. Genotypes, haplotypes, and diplotypes of XPC and risk of bladder cancer. Carcinogenesis. 2006.

Wu X, Gu J, Grossman HB, Amos CI, Etzel C, Huang M, Zhang Q, Millikan RE, Lerner S, Dinney CP, and Spitz, MR. Bladder Cancer Predisposition: A Multigenic Approach to DNA-Repair and Cell-Cycle-Control Genes. Am J Hum Genet. 78: 464-479, 2006.

Tao Z, Connor RJ, Ashoori F, Dinney CP, Munsell M, Philopena JA, and Benedict WF. Efficacy of a single intravesical treatment with Ad-IFN/Syn 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation. Cancer Gene Ther. 13: 125-130, 2006.

Lin J, Dinney CP, Grossman HB, and Wu X. Personal permanent hair dye use is not associated with bladder cancer risk: evidence from a case-control study. Cancer Epidemiol Biomarkers Prev. 15: 1746-9, 2006.

Kassouf W, Luongo T, Brown G, Adam L, and Dinney CP. Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer. J Urol. 176: 787-92, 2006.

Kassouf W, Leibovici D, Munsell MF, Dinney CP, Grossman HB, and Kamat AM. Evaluation of the relevance of lymph node density in a contemporary series of patients undergoing radical cystectomy. J Urol. 176: 53-7; discussion 57, 2006.

Kassouf W, Leibovici D, Luongo T, Munsell MF, Vakar F, Dinney CP, Grossman HB, and Kamat AM. Relevance of extracapsular extension of pelvic lymph node metastasis in patients with bladder cancer treated in the contemporary era. Cancer. 107: 1491-1495, 2006. 

Kassouf W, Highshaw R, Nelkin GM, Dinney CP, and Kamat AM. Vitamins C and k3 sensitize human urothelial tumors to gemcitabine. J Urol. 176: 1642-16477, 2006.

Kamat AM, Gee JR, Dinney CP, Grossman HB, Swanson DA, Millikan RE, Detry MA, Robinson TL, and Pisters LL The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol. 175: 881-815, 2006.

Kamat AM, and Dinney CP. A combination of intravesical and BCG electromotive mitomycin for high-risk superficial bladder cancer. Nat Clin Pract Urol. 3: 472-473, 2006.

Black PC, Brown GA, and Dinney CP. Should cystectomy only be performed at high-volume hospitals by high-volume surgeons? Curr Opin Urol. 16(5): 344-3449, 2006.

Blehm KN, Spiess PE, Bondaruk JE, Dujka ME, Villares GJ, Zhao YJ, Bogler O, Aldape KD, Grossman HB, Adam L, McConkey DJ, Czerniak BA, Dinney CP, and Bar-Eli M.  Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Clin Cancer Res. 12(15): 4671-4677, 2006.

Wu X, Gu J, Wu TT, Swisher SG, Liao Z, Correa AM, Liu J, Etzel CJ, Amos CI, Huang M, Chiang SS, Milas L, Hittelman WN, and Ajani JA. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer.  J Clin Oncol. Aug 10; 24(23): 3789-3798. 2006.

Lin J, Spitz MR, Dinney CP, Etzel CJ, Grossman HB, and Wu X.  Bladder cancer risk as modified by family history and smoking. Cancer. 14; 107(4): 705-711, 2006.

Siefker-Radtke AO. Systemic chemotherapy options for metastatic bladder cancer. Expert Rev Anticancer Ther.  6/6:877-885, 2006.

Lin J, Dinney CP, Grossman HB, Jhamb M, Zhu Y, Spitz MR, and Wu X. E-cadherin promoter polymorphism (C-160A) and risk of recurrence in patients with superficial bladder cancer. Clin Genet.  70(3): 240-245, 2006.

Kassouf W, Swanson D, Kamat AM, Leibovici D, Siefker-Radtke A, Munsell MF, Grossman HB, and Dinney CP. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the MD Anderson Cancer Center experience. J Urol.  175(6): 2058-2062, 2006.

Busby JE, Brown GA, Tamboli P, Kamat AM, Dinney CP, Grossman HB, and Matin SF. Upper urinary tract tumors with nontransitional histology: a single-center experience.  Urology.  67(3): 518-523, 2006.

Sabichi A, Keyhani A, Tanaka N, Delacerda J, Lee IL, Zou C, Zhou JH, Benedict WF, and Grossman HB. Characterization of a panel of cell lines derived from urothelial neoplasms: genetic alterations, growth in vivo and the relationship of adenoviral mediated gene transfer to coxsackie adenovirus receptor expression. J Urol. 175(3 Pt 1): 1133-1137, 2006.

2005

Zhao H, Liang D, Grossman HB, and Wu X. Glutathione peroxidase 1 gene polymorphism and risk of recurrence in patients with superficial bladder cancer. Urology. 66: 769-774, 2005.

Zhao H, Grossman HB, Delclos GL, Hwang LY, Troisi CL, Chamberlain RM, Chenoweth MA, Zhang H, Spitz MR, and Wu X. Increased plasma levels of angiogenin and the risk of bladder carcinoma: from initiation ot recurrence. Cancer . 104: 30-35, 2005.

Mohamedali KA, Kedar D, Sweeney P, Kamat A, Davis DW, Eve BY, Huang S, Thorpe PE, Dinney CP, and Rosenblum MG. The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors. Cancer Res.  65(22): 10524-10535, 2005.

Kassouf W, Dinney CP, Brown G, McConkey DJ, Diehl AJ, Bar-Eli M, and Adam L.Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. Urologic Clinics of North America.  32: 239-246, 2005.

Adam L, Kassouf W, and Dinney CP. Clinical applications for targeted therapy in bladder cancer.  Neoplasia. 7: 912-920, 2005.

Davis DW, Takamori R, Raut CP, Xiong HQ, Herbst RS, Stadler WM, Heymach JV, Demetri GD, Rashid A, Shen Y, Wen S, Abbruzzese JL, and McConkey DJ. Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668. Clin Cancer Res. 11: 678-689, 2005.

Gu J, Zhao H, Dinney CP, Zhu Y, Leibovici D, Bermejo CE, Grossman HB, and Wu X. Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer. Clin Cancer Res. 11: 1408-1415, 2005.

Kim JH, Tuziak T, Hu L, Wang Z, Bondaruk J, Kim M, Fuller G, Dinney C, Grossman HB, Baggerly K, Zhang W, and Czerniak B. Alterations in transcription clusters underlie development of bladder cancer along papillary and nonpapillary pathways.  Lab Invest. 85: 532-549, 2005.

Lashinger, LM, Zhu K, Williams SA, Shrader M, Dinney CP, and McConkey DJ. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. Cancer Res.  65: 4902-4908, 2005.

Leibovici D, Grossman HB, Dinney CP, Millikan RE, Lerner S , Wang Y, Gu J, Dong Q, and Wu X. Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. Journal of Clinical Oncology. 23: 5746-5756, 2005.

Schabath MB, Delclos GL, Grossman HB, Wang Y, Lerner SP, Chamberlain RM, Spitz MR, and Wu X.Polymorphisms in XPD exons 10 and 23 and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 14: 878-884, 2005.

2004

Arap MA, Lahdenranta J, Hajitou A, Marini FC III, Wood CG, Wright KC, Fueyo J, Arap W, and Pasqualini R. Model of unidirectional transluminal gene transfer.  Molecular Therapy. 9: 305-310, 2004.

Benedict WF, Tao Z, Kim C-S, Zhang X, Zhou JH, Adam L, McConkey DJ, Papageorgiou A, Munsell M, Philopena J, Engler H, Demers W, Maneval DC, Dinney CPN, and Connor RJ. Intravesical Ad-IFNa causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFNa protein. Molecular Therapy. 10:525-532, 2004.

Davis DW, Inoue K, Dinney CP, Hicklin DJ, Abbruzzese JL, and McConkey DJ. Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts. Cancer Res.  64(13): 4601-4610, 2004.

 Davis DW, Shen Y, Mullani NA, Wen S, Herbst RS, O'Reilly M, Abbruzzese JL, and McConkey DJ. Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors. Clin Cancer Res. 10(1 Pt 1): 33-42, 2004.

 Dinney CPN, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, Kamat A, Siefker-Radtke AO, Adam L, Tuziak T, Sabichi AL, Grossman HB, Benedict WF, and Czerniak B. Focus on bladder cancer (editorial). Cancer Cell. 6(2):111-116, 2004.

 Hazra A, Grossman HB, Zhu Y, Luo S, Spitz MR, and Wu X. Benzo[a]pyrene diol epoxide-induced 9p21 aberrations associated with genetic predisposition to bladder cancer. Genes Chromosomes Cancer. 41(4): 330-338, 2004.

Highshaw RA, McConkey DJ, and Dinney CP. Integrating basic science and clinical research in bladder cancer: update from the first bladder Specialized Program of Research Excellence (SPORE). Current Opinion in Urology. 14(5): 295-300, 2004.

Lin J, Spitz MR, Wang Y, Schabath, MB, Gorlov IP, Hernandez LM, Pillow PC, Grossman HB, and Wu X. Polymorphisms of folate metabolic genes and susceptibility to bladder cancer: a case-control study. Carcinogenesis. 25(9):1639-1647, 2004.

Papageorgiou A, Lashinger L, Millikan R, Grossman HB, Benedict W, Dinney CP, and McConkey DJ. Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells. Cancer Res. 64(24): 8973-8979, 2004

Schabath MB, Grossman HB, Delclos GL, Hernandez LM, Day RS, Davis BR, Lerner SP, Spitz MR, and Wu X. Dietary carotenoids and genetic instability modify bladder cancer risk. Journal of Nutrition. 134(12):3362-3369, 2004.

Shao L, Lerner SL, Bondaruk J, Czerniak BA, Zeng X, Grossman HB, Spitz MR, and Wu X. Specific chromosome aberrations in peripheral blood lymphocytes are associated with risk of bladder cancer. Genes Chromosomes Cancer. 41(4): 379-389, 2004.

Wu X, Zhao H, Suk R, and Christiani DC. Genetic susceptibility to tobacco-related cancer. Oncogene. 23: 6500-6523, 2004.

Zhu Y, Spitz MR, Amos CI, Lin J, Schabath MB, and Wu X. An evolutionary perspective on single-nucleotide polymorphism screening in molecular cancer epidemiology. Cancer Res. 64: 2251-2257, 2004.

Zhu Y, Spitz MR, Zhang H, Grossman HB, Frazier ML, and Wu X. Methyl-CpG-binding domain 2: a protective role in bladder cancer. Cancer. 100: 1853-1858, 2004.

Siefker-Radtke AO, Dinney CP, Abrahams NA, Moran C, Shen Y, Pisters LL, Grossman HB, Swanson DA, and Millikan RE. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the MD Anderson cancer experience. J Urol. 172(2): 481-484, Aug 2004.

Kamat AM, Karashima T, Davis DW, Lashinger L, Bar-Eli M, Millikan R, Shen Y, Dinney CP, and McConkey DJ. The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Molecular Cancer Therapeutics. 3(3): 279-290, Mar 2004.

Zhu Y, Spitz MR, Amos CI, Lin J, Schabath MB, and Wu X. An evolutionary perspective on single-nucleotide polymorphism screening in molecular cancer epidemiology. Cancer Res. 64: 2251-2257, 2004.

Slaton JW, Millikan R, Inoue K, Karashima T, Czerniak B, Shen Y, Yang Y, Benedict WF, and Dinney CP. Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy. J Urol. 171(2 Pt 1): 570-574, 2004.

Siefker-Radtke AO, Walsh GL, Pisters LL, Shen Y, Swanson DA, Logothetis CJ, and Millikan RE. Is there a role for surgery in the management of metastatic urothelial cancer? The MD Anderson experience. J Urol. 171(1): 145-148, Jan 2004.

2003

Tanaka M, Gee JR, De La Cerda J, Rosser CJ, Zhou JH, Benedict WF, and Grossman HB. Noninvasive detection of bladder cancer in an orthotopic murine model with green fluorescence protein cytology. J Urol. 170(3): 975-978, 2003.

Mian BM, Dinney CP, Bermejo CE, Sweeney P, Tellez C, Yang XD, Gudas JM, McConkey DJ, and Bar-Eli M. Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB. Clin Cancer Res. 9(8): 3167-3175, 2003.

Wu X, Amos CI, Zhu Y, Zhao H, Grossman BH, Shay JW, Luo S, Hong WK, and Spitz MR. Telomere Dysfunction: A Cancer Predisposition Factor? Journal of the National Cancer Institute. 95(16): 1211-1218, 2003.

Karashima T, Sweeney P, Kamat A, Huang S, Kim SJ, Bar-Eli M, McConkey DJ, and Dinney CP. Nuclear factor-kappaB mediates angiogenesis and metastasis of human bladder cancer through the regulation of interleukin-8.  Clin Cancer Res. 9(7): 2786-2797, 2003.

Sweeney P, Millikan R, Donat M, Wood CG, Radtke AS, Pettaway CA, Grossman HB, Dinney CPN, Swanson DA, and Pisters LL. Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? J Urol. 169(6): 2113-2117, 2003.

Pagliaro LC, Keyhani A, Williams D, Woods D, Liu B, Perrotte P, Slaton JW, Merritt JA, Grossman HP, and Dinney CP. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: A phase I study of p53 gene therapy.  Journal of Clinical Oncology. 15:2247-2253, 2003.

Park SJ, Zhao H, Spitz MR, Grossman HB, and Wu X. An association between NQO1 genetic polymorphism and risk of bladder cancer. Mutat Res. 536(1-2):131-7, 2003.

Ardelt PU, Wood CG, Chen L, Mintz PJ, Moya C, Arap MA, Wright KC, Pasqualini R, and Arap W. Targeting urothelium: Ex vivo assay standardization and selection of internalizing ligands. J Urol. 169(4): 1535-1540, 2003.

Siefker-Radtke AO, Gee J, Shen Y, Wen S, Daliani D, Millikan RE, and Pisters LL. Multimodality management of urachal carcinoma: the MD Anderson Cancer Center experience. J Urol. 169(4):1295-1298, 2003.

Schabath MB, Spitz MR, Grossman HB, Zhang K, Dinney CP, Zheng PJ, and Wu X. Genetic instability in bladder cancer assessed by the comet assay. J Natl Cancer Inst. 95: 540-547, 2003.

Hazra A, Chamberlain RM, Grossman HB, Zhu Y, Spitz MR, and Wu X. Death receptor 4 and bladder cancer risk. Cancer Res. 63: 1157-1159, 2003.

 Zhao H, Grossman HB, Spitz MR, Lerner SP, Zhang K, and Wu X. Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk. J Urol. 169(2): 714-717, 2003.

 Zhang X, Multani AS, Zhou JH, Shay JW, McConkey D, Dong L, Kim CS, Rosser CJ, Pathak S, and Benedict WF. Adenoviral-mediated retinoblastoma 94 produces rapid telomere erosion, chromosomal crisis, and caspase-dependent apoptosis in bladder cancer and immortalized human urothelial cells, but not in normal urothelial cells. Cancer Res. 63: 760-765, 2003.

Zheng L, Wang Y, Schabath MB, Grossman HB, and Wu X. Sulfotransferase 1A1 (SULT1A1) polymorphism and bladder cancer risk: a case-control study. Cancer Letters. 8;202(1): 61-69, 2003.

2002

Yamashita M, Rosser CJ, Zhou JH, Zhang XQ, Connor RJ, Engler H, Maneval DC, Karashima T, Czerniak BA, Dinney CP, and Benedict WF. Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer. Cancer Gene Ther. 9(8): 687-91, 2002.

Zhou JH, Rosser CJ, Tanaka M, Yang M, Baranov E, Hoffman RM, and Benedict WF. Visualizing superficial human bladder cancer cell growth in vivo by green fluorescent protein expression. Cancer Gene Ther. 9(8): 681-686, 2002.

Izawa JI, Sweeney P, Perrotte P, Kedar D, Dong Z, Slaton JW, Karashima T, Inoue K, Benedict WF, and Dinney CP. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. Clin Cancer Res. 8(4): 1258-1270, 2002.

 2001

Clifford JL, Sabichi AL, Zou C, Yang X, Steele VE, Kelloff GJ, Lotan R, and Lippman SM. Effects of novel phenylretinamides on cell growth and apoptosis in bladder cancer. Cancer Epidemiol Biomarkers Prev. 10: 391-395, 2001.

Slaton JW, Karashima T, Perrotte P, Inoue K, Kim SJ, Izawa J, Kedar D, McConkey DJ, Millikan R, Sweeney P, Yoshikawa C, Shuin T, and Dinney CP. Treatment with Low-Dose Interferon-alpha Restores the Balance between Matrix Metalloproteinase-9 and E-Cadherin Expression in Human Transitional Cell Carcinoma of the Bladder.  Clin Cancer Res. 7: 2840-2853, 2001.

Tanaka M, Fraizer GC, De La Cerda J, Cristiano RJ, Liebert M, and Grossman HB. Connexin 26 enhances the bystander effect in HSVtk/GCV gene therapy for human bladder cancer by adenovirus/PLL/DNA gene delivery. Gene Ther. 8: 139-148, 2001.

Millikan R, Dinney C, Swanson D, Sweeney P, Ro JY, Smith TL, Williams D and Logothetis C. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. Journal of Clinical. Oncology. 19: 4005-4013, 2001.

Kram A, Li L, Zhang RD, Yoon DS, Ro JY, Johnston D, Grossman HB, Scherer S, and Czerniak B. Mapping and genome sequence analysis of chromosome 5 regions involved in bladder cancer progression. Lab Invest. 81: 1039-1048, 2001.

Yoon DS, Li L, Zhang RD, Kram A, Ro JY, Johnston D, Grossman HB, Scherer S, and Czerniak B. Genetic mapping and DNA sequence-based analysis of deleted regions on chromosome 16 involved in progression of bladder cancer from occult preneoplastic conditions to invasive disease. Oncogene. 20(36): 5005-5014, 2001.

 Izawa JI, Slaton JW, Kedar D, Karashima T, Perrotte P, Czerniak B, Grossman HB, and Dinney CP.  Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder. Oncology Rep. 8: 9-15, 2001.

 Lance, RS, Dinney CPN, Swanson D, Babaian RJ, Pisters LL, Palmer JL, and Grossman HB. Radical cystectomy for invasive bladder cancer in the octogenarian. Oncology Rep. 8: 723-726, 2001.

2000

Watanabe T, Shinohara N, Sazawa A, Harabayashi T, Ogiso Y, Koyanagi T, Takiguchi M, Hashimoto A, Kuzumaki N, Yamashita M, Tanaka M, Grossman HB, and Benedict WF.  An improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies. Cancer Gene Ther.  7: 1575-1580, 2000.

Inoue K, Perrotte P, Wood CG, Slaton JW, Sweeney P, and Dinney CP. Gene therapy of human bladder cancer with adenovirus-mediated antisense basic fibroblast growth factor. Cancer Res. 6: 4422-4431, 2000.

Inoue K, Slaton JW, Karashima T, Yoshikawa C, Shuin T, Sweeney P, Millikan R, and Dinney CP. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res. 6: 4866-4873, 2000.

Inoue K, Slaton JW, Perrotte P, Davis DW, Bruns CJ, Hicklin DJ, McConkey DJ, Sweeney P, Radinsky R, and Dinney CP.  Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res. 6: 4874-4884, 2000.

Inoue K, Slaton JW, Davis DW, Hicklin DJ, McConkey DJ, Karashima T, Radinsky R, and Dinney CP. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Clin Cancer Res. 6: 2635-2643, 2000.

Tanaka M, Koul D, Davies MA, Liebert M, Steck PA, and Grossman HB. MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells. Oncogene. 19: 5406-5412, 2000.

Thall PF, Millikan RE, and Sung HG. Evaluating multiple treatment courses in clinical trials. Stat Med. 19: 1011-1028, 2000.

Perrotte P, Wood M, Slaton JW, Wilson DR, Pagliaro L, Price RE, and Dinney CP. Biosafety of in vivo adenovirus-p53 intravesical administration in mice. Urology. 56: 155-159, 2000.


© 2014 The University of Texas MD Anderson Cancer Center